Date Published
Country
Source
Reports
- 1643 results found
-
High-Expenditure Medicare Drugs Often Qualified for Orphan Drug Act incentives deSigned to Encourage the Development of Treatments for Rare Diseases
The Orphan Drug Act (ODA) provides financial incentives to encourage the development of drugs for rare diseases or conditions for which treatments might not be developed otherwise. -
Stemming the High and Rising Costs of Prescription Drugs
This initiative involves collaborating with decision makers and developing policies to reduce prescription drug spending without stifling innovation in the pharmaceutical industry.Comments
No comments yet. Create an account and log in to post a comment.
-
European Health Union: Towards a reform of EU's pharmaceutical legislation
As part of its work to create a future-proof and crisis-resilient regulatory framework for the pharmaceutical sector, the Commission has published a public consultation on the revision of the EU's pharmaceutical legislation.Comments
No comments yet. Create an account and log in to post a comment.
-
A Double Dose of Inequality: Pharma Companies and the Covid-19 Vaccines Crisis
New report shows leading Covid-19 vaccine pharma companies fuelling unprecedented human rights crisis.Comments
No comments yet. Create an account and log in to post a comment.
-
ICER Releases Draft Evidence Report on Therapies for Severe Asthma
Tezepelumab for Severe AsthmaComments
No comments yet. Create an account and log in to post a comment.
-
Value-Based Pricing of Prescription Drugs Benefits Patients and Promotes Innovation
This report makes the case that value-based pricing has the potential to better serve the American public by promoting research into drug products with greater clinical benefit that help meet the country’s health care needs.Comments
No comments yet. Create an account and log in to post a comment.
-
Comprehensive Plan for Addressing High Drug Prices
A Report in Response to the Executive Order on Competition in the American EconomyComments
No comments yet. Create an account and log in to post a comment.
-
WHO Compendium of Innovative Health Technologies for Low-Resource Settings 2021. COVID-19 and Other Health Priorities
Health technologies are essential for a functioning health system.Comments
No comments yet. Create an account and log in to post a comment.
-
WORLD PREVIEW 2021 Outlook to 2026
This year the World Preview focuses on how biopharma companies are navigating this new landscape, and the potential lasting effects of the pandemic.Comments
No comments yet. Create an account and log in to post a comment.
-
Cutting Square Deals: Drug Prices, Regulation, and Patent Protection
Canada’s efforts to reduce pharmaceutical prices should not come at the cost of contributing our fair share to developing new treatment innovations, and should rely more on negotiations with manufacturers than regulation.Comments
No comments yet. Create an account and log in to post a comment.
-
ICER Releases Draft Evidence Report on Mavacamten for Hypertrophic Cardiomyopathy
The Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the comparative clinical effectiveness and value of mavacamten (MyoKardia and Bristol-Myers Squibb) for the treatment of hypertrophic cardiomyopathy.Comments
No comments yet. Create an account and log in to post a comment.
-
MIRROR, MIRROR 2021
Reflecting Poorly: Health Care in the U.S. Compared to Other High-Income CountriesComments
No comments yet. Create an account and log in to post a comment.
-
NICE Changes to Provide Faster, Fairer Access to New Drugs and Devices
NICE is changing how it assess new drugs, devices, diagnostics and digital technologies to provide faster and fairer access in the NHS. The changes will also improve the way it works with patients, the NHS and the life sciences industry.Comments
No comments yet. Create an account and log in to post a comment.
-
Will Reducing Drug Prices Slow Innovation?
The pharmaceutical industry has long argued that high drug prices reflect the high cost of innovation and that reducing drug prices would necessarily slow the pipeline of new drugs.@CIDSAexperts, @WestHealth, @bentleyu
Comments
No comments yet. Create an account and log in to post a comment.
-
An Urgent Call to Raise the Bar in Oncology
Several factors that contribute to approvals of low-value oncology treatments are addressed, including issues with clinical trials, bias in reporting, regulatory agency shortcomings and drug pricing.Comments
No comments yet. Create an account and log in to post a comment.
Comments